Semaglutide vs Tirzepatide: Which GLP-1 Is Better for Weight Loss?
Compare semaglutide (Ozempic/Wegovy) vs tirzepatide (Mounjaro/Zepbound) for weight loss. Side-by-side analysis of effectiveness, side effects, cost, and availability.
Bottom Line
Based on current research, tirzepatide comes out ahead in this comparison. See the full breakdown below for context — the best choice depends on your specific situation.
| Dimension | semaglutide | tirzepatide | Notes |
|---|---|---|---|
| Weight Loss Efficacy | 15-17% | 20-26% | Tirzepatide shows superior weight loss in SURMOUNT vs STEP trials (26.6% vs 16.9% at highest doses). |
| Mechanism | GLP-1 only | GLP-1 + GIP dual | Tirzepatide activates both GLP-1 and GIP receptors, providing dual incretin action. |
| FDA Status | Approved (obesity) | Approved (obesity) | Both FDA-approved for chronic weight management. Semaglutide as Wegovy, tirzepatide as Zepbound. |
| Nausea/GI Side Effects | Moderate-High | Moderate | Both cause GI side effects. Some data suggests tirzepatide may be slightly better tolerated. |
| Dosing Frequency | Weekly | Weekly | Both administered as once-weekly subcutaneous injections. |
| Monthly Cost | $1,000-1,350 | $1,000-1,100 | Brand-name costs similar. Compounded versions vary widely ($150-500/month). |
| Insurance Coverage | Moderate | Growing | Semaglutide has longer track record with insurers. Tirzepatide coverage expanding rapidly. |
| Muscle Preservation | Poor | Slightly Better | Both cause lean mass loss. Tirzepatide may preserve slightly more muscle due to GIP action. |
Learn more about each peptide
Semaglutide
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes that has demonstrated significant weight loss effects in clinical trials. It is sold under the brand names Ozempic (diabetes) and Wegovy (weight management).
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown greater weight loss than semaglutide in head-to-head trials. It is sold under the brand names Mounjaro (diabetes) and Zepbound (weight management).
More comparisons
Weekly peptide research updates
New studies, GLP-1 news, protocol insights, and weight loss data — delivered every week. Free. No spam.
Reviewed by Fat Man in the Arena · Updated March 2026
Medical Disclaimer: This comparison is for informational purposes only. Individual responses vary. Always consult a qualified healthcare provider before starting any peptide protocol.